Scientia Advisors Management Consultant and Managing Partner, Harry Glorikian Will Speak at the Fifteenth International Molecular Medicine Tri-Conference in San Francisco
Scientia Advisors Management Consultant and Managing Partner, Harry Glorikian will be an introductory speaker at the Fifteenth International Molecular Medicine Tri-Conference, held at the Moscone North Convention Center, San Francisco, CA from March 25-28, 2008.
Cambridge, MA, February 04, 2008 --(PR.com)-- Harry Glorikian will be providing the Plenary Keynote Introduction ahead of Dr. Clayton M. Christensen’s keynote presentation titled, “Diagnosing the Disease: Disruptive Innovation in Healthcare” at 8:00am PST on March 25, 2008.
Disruptive innovations are increasingly changing today’s health care landscape just as they have continued to change the face of many other industries. Historically, it has been common practice to rely on intuitive medicine in the face of uncertainty regarding a patient’s diagnosis and disease state. Now, however, molecular biology promises to play a key role in advancing medical practice into a new phase called precision medicine. This transformation in healthcare will not only lead to reduced costs but also increased therapeutic efficacy and predictability.
www.tri-conference.com
Harry Glorikian’s experience allows him to intellectually address a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides both a unique and insightful perspective. Harry has more than 15 years of experience in the life science industry, developing and executing key strategic acquisitions and licensing arrangements which target revenue growth. Harry currently leads Scientia, which includes the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. Scientia’s clients range from emerging innovators to global market leaders.
###
Disruptive innovations are increasingly changing today’s health care landscape just as they have continued to change the face of many other industries. Historically, it has been common practice to rely on intuitive medicine in the face of uncertainty regarding a patient’s diagnosis and disease state. Now, however, molecular biology promises to play a key role in advancing medical practice into a new phase called precision medicine. This transformation in healthcare will not only lead to reduced costs but also increased therapeutic efficacy and predictability.
www.tri-conference.com
Harry Glorikian’s experience allows him to intellectually address a broad range of areas within life sciences. His direct experience in sales, marketing, business development, and intellectual property combined with his technical and market knowledge provides both a unique and insightful perspective. Harry has more than 15 years of experience in the life science industry, developing and executing key strategic acquisitions and licensing arrangements which target revenue growth. Harry currently leads Scientia, which includes the management of consulting teams, new business development, and intellectual capital development. His client engagements have involved comprehensive go-to-market plans in the areas of diagnostics, genomic, proteomics, cell biology, cellular therapy and consumables & services groups. Scientia’s clients range from emerging innovators to global market leaders.
###
Contact
Scientia Advisors
Tal Dinnar
617-401-2330
www.scientiaadv.com
Tal Dinnar
617-401-2330
www.scientiaadv.com
Contact
Categories